IFP Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

IFP Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3	Closed	-$1	–	4975
2025 Q1	$1	Hold	3	–	–	﹤0.01%	4292
2024 Q4	$2	Buy	+3	New	+$2	﹤0.01%	4583
2023 Q1	–	Sell	-8	Closed	-$1K	–	3981
2022 Q4	$1K	Hold	8	–	–	﹤0.01%	4388
2022 Q3	$1K	Hold	8	–	–	﹤0.01%	4595
2022 Q2	$1K	Hold	8	–	–	﹤0.01%	4370
2022 Q1	$1K	Buy	+8	New	+$12	﹤0.01%	4369
2021 Q4	–	Sell	-11,077	Closed	-$28K	–	3432
2021 Q3	$28K	Buy	11,077 +8,000	+260%	+$20.5K	﹤0.01%	1839
2021 Q2	$9K	Hold	3,077	–	–	﹤0.01%	2257
2021 Q1	$8K	Buy	3,077 +2,000	+186%	+$4.8K	﹤0.01%	2226
2020 Q4	$2K	Hold	1,077	–	–	﹤0.01%	2629
2020 Q3	$1K	Hold	1,077	–	–	﹤0.01%	2657
2020 Q2	$1K	Hold	1,077	–	–	﹤0.01%	2556
2020 Q1	$1K	Hold	1,077	–	–	﹤0.01%	2554
2019 Q4	$1K	Hold	1,077	–	–	﹤0.01%	2682
2019 Q3	$1K	Buy	+1,077	New	+$1.11K	﹤0.01%	2884
2019 Q1	–	Sell	-15	Closed	–	–	2938
2018 Q4	$0	Buy	+15	New	+$23	﹤0.01%	3720
2017 Q4	–	Sell	-34	Closed	–	–	3965
2017 Q3	$0	Hold	34	–	–	﹤0.01%	4142
2017 Q2	$0	Hold	34	–	–	﹤0.01%	4156
2017 Q1	$0	Hold	34	–	–	﹤0.01%	4064
2016 Q4	$0	Hold	34	–	–	﹤0.01%	4060
2016 Q3	$0	Hold	34	–	–	﹤0.01%	3968
2016 Q2	$0	Buy	+34	New	+$83	﹤0.01%	3952

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

IFP Advisors's LCTX Position: Q2 2025 in Review

IFP Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q2 2025, closing a stake of 3 shares — an estimated $1 sold.

IFP Advisors first reported a position in LCTX in Q2 2016 and held it in 22 quarters. The position peaked at $28K in Q3 2021. 129 funds tracked by Wall St. Rank hold LCTX as of Q2 2025.

IFP Advisors reported no remaining Lineage Cell Therapeutics position as of Q2 2025 after selling out during the quarter.
IFP Advisors sold 3 Lineage Cell Therapeutics shares in Q2 2025, an estimated $1.
IFP Advisors first reported a position in Lineage Cell Therapeutics in Q2 2016 and held it in 22 quarters.
IFP Advisors's Lineage Cell Therapeutics position peaked at $28K in Q3 2021.
129 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2025.

Based on IFP Advisors's 13F filing for Q2 2025, filed 24 Jul 2025.